Jade Biosciences Management
Management criteria checks 0/4
Jade Biosciences' CEO is Tom Frohlich, appointed in Oct 2024, has a tenure of 1.25 years. directly owns 0.013% of the company’s shares, worth $97.81K. The average tenure of the management team and the board of directors is 1.3 years and 1.4 years respectively.
Key information
Tom Frohlich
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.01% |
| Management average tenure | 1.3yrs |
| Board average tenure | 1.4yrs |
Recent management updates
Recent updates
CEO
Tom Frohlich (49 yo)
Mr. Tom Frohlich is Chief Executive Officer & Director of Jade Biosciences, Inc. since October 2024. Mr. Frohlich serves as Independent Director of Nested Therapeutics since February 2024. He served as the...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.3yrs | no data | 0.013% $ 97.8k | |
| CFO & Treasurer | less than a year | no data | no data | |
| Chief Scientific Officer & Head of R&D | 1.4yrs | no data | 0.50% $ 3.7m | |
| General Counsel & Corporate Secretary | 1.3yrs | no data | no data | |
| Senior Vice President of People | no data | no data | no data | |
| Senior Vice President of Chemistry | no data | no data | no data | |
| Senior Vice President of Finance | no data | no data | no data | |
| Senior Vice President of Regulatory & Quality | no data | no data | no data | |
| Senior Vice President of Development Operations | no data | no data | no data | |
| Senior Vice President | no data | no data | no data |
Experienced Management: JBIO's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.3yrs | no data | 0.013% $ 97.8k | |
| Independent Chairman | 1.3yrs | no data | 0% $ 0 | |
| Independent Director | 1.5yrs | no data | no data | |
| Independent Director | 1.5yrs | no data | no data | |
| Independent Director | 1.3yrs | no data | 0% $ 0 | |
| Independent Director | 1.5yrs | no data | 0.19% $ 1.4m |
Experienced Board: JBIO's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/25 10:10 |
| End of Day Share Price | 2026/01/23 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jade Biosciences, Inc. is covered by 7 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julian Harrison | BTIG |
| Vamil Divan | Guggenheim Securities, LLC |
| Yu He | H.C. Wainwright & Co. |